New ALK inhibitor – OTX015

Oncoethix, a European consortium, has published a presentation on preclinical results for a new ALK inhibitor called OTX015. When combined with Crizotinib it has greater inhibitory effect. It also inhibits: BET and BRD families of reader proteans. The BET inhibition may include a promising KRAS inhibitor as well.

http://www.oncoethix.com/wp-content/uploads/2014/05/AACR-6-Lung.pdf

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply